Abstract

Small nucleotide variants in non-coding regions of the genome can alter transcriptional regulation, leading to changes in gene expression which can activate oncogenic gene regulatory networks. Melanoma is heavily burdened by non-coding variants, representing over 99% of total genetic variation, including the well-characterized TERT promoter mutation. However, the compendium of regulatory non-coding variants is likely still functionally under-characterized. We developed a pipeline to identify hotspots, i.e. recurrently mutated regions, in melanoma containing putatively functional non-coding somatic variants that are located within predicted melanoma-specific regulatory regions. We identified hundreds of statistically significant hotspots, including the hotspot containing the TERT promoter variants, and focused on a hotspot in the promoter of CDC20. We found that variants in the promoter of CDC20, which putatively disrupt an ETS motif, lead to lower transcriptional activity in reporter assays. Using CRISPR/Cas9, we generated an indel in the CDC20 promoter in human A375 melanoma cell lines and observed decreased expression of CDC20, changes in migration capabilities, increased growth of xenografts, and an altered transcriptional state previously associated with a more proliferative and less migratory state. Overall, our analysis prioritized several recurrent functional non-coding variants that, through downregulation of CDC20, led to perturbation of key melanoma phenotypes.

A non-coding variant upstream of the CDC20 promoter leads to down-regulation of CDC20 expression and up-regulation of a more proliferative and melanocytic transcriptional program that may aid in accelerating tumor growth.

Details

Title
Functional analysis of recurrent CDC20 promoter variants in human melanoma
Author
Godoy, Paula M. 1 ; Oyedeji, Abimbola 2   VIAFID ORCID Logo  ; Mudd, Jacqueline L. 2   VIAFID ORCID Logo  ; Morikis, Vasilios A. 3 ; Zarov, Anna P. 1   VIAFID ORCID Logo  ; Longmore, Gregory D. 4   VIAFID ORCID Logo  ; Fields, Ryan C. 2   VIAFID ORCID Logo  ; Kaufman, Charles K. 5   VIAFID ORCID Logo 

 Washington University School of Medicine, Division of Medical Oncology, Department of Medicine and Department of Developmental Biology, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002) 
 Washington University School of Medicine, Department of Surgery, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University in Saint Louis, Siteman Cancer Center, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002) 
 Washington University School of Medicine, Departments of Medicine (Oncology) and Cell Biology and Physiology and the ICCE Institute, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002) 
 Washington University in Saint Louis, Siteman Cancer Center, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University School of Medicine, Departments of Medicine (Oncology) and Cell Biology and Physiology and the ICCE Institute, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002) 
 Washington University School of Medicine, Division of Medical Oncology, Department of Medicine and Department of Developmental Biology, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002); Washington University in Saint Louis, Siteman Cancer Center, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002) 
Pages
1216
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2895071767
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.